Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06337942 · ClinicalTrials.gov registry record · NA
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
A NA study of Bladder Cancer and Kidney Failure, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06337942: Recruiting NA study of Bladder Cancer and Kidney Failure, sponsored by University of California, Los Angeles.
NCT06337942 is a NA study of Bladder Cancer and Kidney Failure that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 5 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06337942, a NA study of Bladder Cancer and Kidney Failure, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to demonstrate the feasibility of bladder transplantation in patients with terminal bladder diseases who would benefit from a new bladder or a combined kidney and bladder transplant. The main questions it aims to answer are: * Is human bladder transplantation feasible and safe? * How will the new bladder function in terms of storage and emptying? Participants will undergo a bladder-only or combined kidney and bladder transplantation. They will then be followed for two years to evaluate the efficacy, safety, and functionality of the bladder transplant.
Primary Outcome
The technical success of bladder transplantation will be evaluated. Technical success is defined as sustained and adequate perfusion to the bladder to maintain viability, as assessed through cystoscopic visual inspection and imaging, including ultrasound and cross-sectional imaging.
Conditions Studied
Interventions
- PROCEDURE Bladder Transplantation
- PROCEDURE Combined Kidney and Bladder Transplantation
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2028-01 |
| Phase | NA |
What NCT06337942 shows while recruiting
NCT06337942 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bladder Transplantation is the first listed.
NCT06337942 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06337942 about?
NCT06337942 is a clinical study titled "Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study". The goal of this clinical trial is to demonstrate the feasibility of bladder transplantation in patients with terminal bladder diseases who would benefit from a new bladder or a combined kidney and bladder transplant. The main questions it aims to answer are: * Is human bladder transplantation feas...
What is the current status of trial NCT06337942?
This trial is currently recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2025-02-01. Estimated completion is 2028-01.
What conditions does trial NCT06337942 study?
This clinical trial studies the following conditions: Bladder Cancer, Kidney Failure, Bladder Disease, Bladder, Neurogenic.
What interventions are being tested in trial NCT06337942?
The interventions under investigation include: Bladder Transplantation (PROCEDURE), Combined Kidney and Bladder Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT06337942?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06337942 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06337942's enrollment target sits among peer trials
5 175th of 175 the lowest of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI